18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial

Saskia A Cooke,Dirk de Ruysscher,Bart Reymen,Maarten Lambrecht,Gitte Fredberg Persson,Corinne Faivre-Finn,Edith M T Dieleman,Rolf Lewensohn,Judi N A van Diessen,Karolina Sikorska,Ferry Lalezari,Wouter Vogel,Wouter van Elmpt,Eugène M F Damen,Jan-Jakob Sonke,José S A Belderbos

Radiotherapy and Oncology（2023）

引用 8|浏览7

暂无评分

摘要

•Multi-center trial testing two personalised radiotherapy dose-escalation strategies.•107 patients with stage II/III disease and a large primary tumour were randomised.•24 fractions escalated dose to the whole primary tumour or the PET-subvolume.•Freedom from local failure rates were high (1-year > 90 %) in both arms.•Unexpected increased rates of grade 5 events were seen in both arms.

查看译文

关键词

Locally advanced non-small cell lung cancer,Radiotherapy,Dose escalation,18F-FDG-PET,Hypofractionation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要